United States

Takara Bio Inc (4974.T)

4974.T on Tokyo Stock Exchange

25 May 2017
Change (% chg)

¥-13 (-0.86%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low


Chart for 4974.T


TAKARA BIO INC. is a biotechnological company. The Company has three business segments. The Genetic Engineering Research segment is involved in the research and development of biotechnology; the manufacture of research reagents; the sale, maintenance and repair of physics and chemistry equipment, such as reaction temperature... (more)


Beta: 1.71
Market Cap(Mil.): ¥182,911.30
Shares Outstanding(Mil.): 120.42
Dividend: --
Yield (%): 0.26


  4974.T Industry Sector
P/E (TTM): 135.29 141.29 17.43
EPS (TTM): 11.23 -- --
ROI: 2.22 2.17 -5.41
ROE: 2.26 0.10 -4.69

BRIEF-Takara Holdings' subsidiary Takara Bio says merger between US-based units

* Says the company's wholly owned US-based sub-subsidiary Takara Bio USA Inc plans to merge with co's other two wholly owned US-based sub-subsidiaries Rubicon Genomics Inc and WaferGen Bio-systems Inc, with effective date on March 31 (for Rubicon) and May 31 (for WaferGen)respectively

Mar 27 2017

BRIEF-Takara Holdings unit fully acquires WaferGen Bio-systems for $35.9 mln

* Says its subsidiary Takara Bio Inc's unit, Takara Bio USA Holdings Inc., fully acquired WaferGen Bio-systems, Inc at $35.9 million

Mar 01 2017

BRIEF-Takara Bio to start phase I/II clinical trials of gene therapy for sarcoma treatment

* Says the co to start phase I/II clinical trials of gene therapy for treatment of sarcoma

Jan 24 2017

BRIEF-Takara Bio's unit completes acquisition of Rubicon Genomics

* Says its wholly owned subsidiary Takara Bio USA Holdings Inc completes acquisition of Rubicon Genomics, Inc on Jan. 17 (US local time)

Jan 17 2017

More From Around the Web

Earnings vs. Estimates